NCT06355232View on ClinicalTrials.gov

Covid-19 and Influenza Oral Vaccine Study

PHASE1RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

May 1, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
covid19 InfectionInfluenza, Human
Interventions
BIOLOGICAL

Covid-19 vaccine

Recombinant SARS-CoV-2 spike protein with Advax-CpG55.2 adjuvant

BIOLOGICAL

Influenza vaccine

Inactivated seasonal influenza vaccine with Advax-CpG55.2 adjuvant

Trial Locations (1)

5042

RECRUITING

ARASMI, Adelaide

All Listed Sponsors
collaborator

Australian Respiratory and Sleep Medicine Institute Ltd

UNKNOWN

lead

Vaxine Pty Ltd

INDUSTRY